Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO ...
Updated data for Nectin-4 targeting zelenectide pevedotin in mUC showed a 45% ORR, 11.1 months median duration of response, and a well-tolerated safety profile. EphA2-targeting BT5528 demonstrated a 45% ORR in mUC and a differentiated safety profile. Low frequency and severity of treatment-related peripheral neuropathy were observed with zelenectide pevedotin and BT5528. BT7480 showed favorable safety and preliminary antitumor activity in advanced Nectin-4-associated solid tumors.
Reference News
Updated data for Nectin-4 targeting zelenectide pevedotin in mUC showed a 45% ORR, 11.1 months median duration of response, and a well-tolerated safety profile. EphA2-targeting BT5528 demonstrated a 45% ORR in mUC and a differentiated safety profile. Low frequency and severity of treatment-related peripheral neuropathy were observed with zelenectide pevedotin and BT5528. BT7480 showed favorable safety and preliminary antitumor activity in advanced Nectin-4-associated solid tumors.